Gender-Specific Phase III Trial For Advanced Non-Small Cell Lung Cancer Approved
Non-Small Cell Lung Cancer
Cell Therapeutics has begun a confirmatory phase III clinical trial of combination chemotherapy for women with advanced non-small cell lung cancer (NSCLC) -- the most lethal cancer facing women today.
The trial, known as PGT307, will focus exclusively on women with pre-menopausal estrogen levels -- a group whose survival is significantly shorter than post-menopausal women. XYOTAX